

NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING AGENDA

OPEN SESSIONS

Venue: Carlyle Room
Date: Saturday, April 28th 2012
Time: 9:00 a.m. – 12:00 p.m.
Chair: Dr. Warren Mason

9:00 am **WELCOME AND INTRODUCTIONS** W. Mason

COMPLETED STUDIES

9:05 am **IND.162:** A Phase I/II study of Temozolomide and RAD001c in Patients with Malignant Glioblastoma Multiforme - Final report and manuscript status W. Mason

TRIALS CLOSED TO ACCRUAL

9:10 am **CE5 (EORTC 22033-26033):** Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study W. Mason

CE.5S: The Socio/behavioural Effects of Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study A. Leis

ACTIVELY ACCRUING TRIALS

9:30 am **CE.6:** A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients N. Laperriere & J. Perry

9:45 am **CEC.1 (EORTC 26053_22054):** Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial W. Mason & C. O'Callaghan

10:00 am **CEC.2 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial) G. Cairncross

10:15 am COFFEE BREAK

ACTIVELY ACCRUING TRIALS (CONTINUED)

10:30 am **CEC.3 (NCCTG N107C):** A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease
D. Roberge & P. Brown

10:45 am **IND.204:** PX866 in Recurrent GBM
M. Pitz

APPROVED TRIALS PENDING ACTIVATION

11:00 am **CEC.4 (ECOG E3F05):** Phase III study of radiotherapy +/- temozolomide for symptomatic or progressive low-grade gliomas
W. Mason & C.O'Callaghan

MISCELLANEOUS

11:15 am Terry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM Project Status Report
G. Cairncross

11:30 am Translational Studies and Tumour Banking
S. Croul

11:45 am Report from IND Committee
H. Hirte

12:00 pm **CLOSING REMARKS**
W.Mason